Article
A novel bioassay for thyroid-blocking immunoglobulins
29 Oct 2024
Abstract excerpt
Background Thyroid-blocking immunoglobulins (TBI) are present in 10%–15% of patients with autoimmune thyroid disease (AITD). TBI affect thyroid function. The analytical performance of a novel TBI bioassay was evaluated. Methods Sera from AITD patients were tested with a cell-based TBI reporter bioassay (Thyretain®) with the expression of a luciferase transgene as readout and a new “Turbo™” TBI bioassay with a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
